Orion Corporation, commonly referred to as Orion, is a Finnish pharmaceutical company headquartered in Espoo, Finland. Founded in 1917, Orion has established itself as a key player in the pharmaceutical and biotechnology industry, with a strong presence in Europe and beyond. The company focuses on developing innovative medicines and diagnostic products, particularly in the fields of oncology, pain management, and central nervous system disorders. Orion's core offerings include prescription pharmaceuticals and over-the-counter products, distinguished by their commitment to quality and research-driven development. With a robust pipeline of new therapies and a reputation for excellence, Orion has achieved notable milestones, including successful collaborations and a growing international market presence. As a trusted name in healthcare, Orion continues to advance its mission of improving patient outcomes through science and innovation.
How does Orion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Orion's score of 57 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Orion Corporation reported total greenhouse gas emissions of approximately 371,000,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 362,000,000 kg CO2e. Specifically, Scope 1 emissions were about 5,625,000 kg CO2e, and Scope 2 emissions (market-based) were approximately 5,330,000 kg CO2e. In 2023, the company’s total emissions were around 417,000,000 kg CO2e, with Scope 3 emissions at about 417,000,000 kg CO2e, Scope 1 at approximately 5,511,000 kg CO2e, and Scope 2 (market-based) at about 8,429,000 kg CO2e. Orion has set ambitious climate commitments, aiming for a 70% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2023 baseline. Additionally, the company targets that 78% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2029. Furthermore, Orion is committed to achieving net-zero emissions by 2050. The company’s near-term targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to reducing greenhouse gas emissions in line with the 1.5°C climate goal. Orion's reduction initiatives are crucial in the context of the pharmaceuticals, biotechnology, and life sciences sector, where sustainability practices are increasingly vital for operational resilience and regulatory compliance.
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 3,740,000 | 0,000,000 | 0,000,000 | - | 0,000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 21,685,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | 000,000,000 | - | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orion is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
